Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Financings Of The Fortnight: IPOs Make A Return In Talecris And Omeros Deals

This article was originally published in The Pink Sheet Daily

Executive Summary

Money continued to flow to big and small biotechs, including nearly a dozen PIPEs or registered direct offerings.

You may also be interested in...

Will IPOs Come Back? Investors Watching Anthera; Big Pharma Should Too

Anthera's planned offering will be the first real IPO in 18 months and a good indicator of whether there are signs of life in the biotech IPO market.

Adimab's Search Results Lead to Google Ventures

Adimab CEO Gerngross wouldn't disclose the amount of Series D money raised, but promised "there will be interactions" between Adimab and parent company Google.

Advisory Panel Backs Approval Of Auxilium's Xiaflex, Wants Post-Market Data

Members agree 12-0 that drug is approvable, offer opinion on who should dispense and the amount of training needed.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts